-
Orphan Drug Development: Shelter the World for Patients with Rare Diseases
Time of Update: 2022-11-04
Orphan drug approved by the FDA in the first quarter of 2022 Therapies for rare diseases come in a variety of forms, from traditional small molecule drugs to macromolecular biologics to cell and gene therapies.
-
Market From the limited supply of oxcarbazepine, look at the domestic anti-epileptic drug market pattern
Time of Update: 2022-11-04
Recently, Novartis issued a statement saying that its anti-epileptic drug oxcarbazepine (Qulai) has limited product supply due to the shortage of key raw materials in production. Later, Novartis has t
-
Traditional Chinese medicine also welcomes favorable policies, and the scale of talent team will continue to expand
Time of Update: 2022-11-04
It is understood that in the past 10 years, the scale of China's traditional Chinese medicine talent team has continued to grow, and the number of practicing (assistant) physicians in the category of traditional Chinese medicine has increased steadily year by year, accounting for 14.
-
What factors caused the once-in-a-decade medical winter?
Time of Update: 2022-11-04
When you are in the cold winter, the first thing you should do is not panic. If you're prepared, use the crisis as your best chance. If you are not prepared, start preparing now, you can be stronger t
-
Under the Cold Winter: Top 10 Living Methods for Small and Medium-sized Pharmaceutical Companies
Time of Update: 2022-11-04
At the same time as the spin-off, the independent listing and the merger of the SPAC company were completedFocus on the core pipelineFocus on the core pipelineFaced with financing difficulties, many small and medium-sized biopharmaceutical companies prioritize existing pipelines according to technical advantages, R&D progress, market potential and other factors, tilting funds and resources towards pipelines for priority development, while non-priority R&D pipelines are suspended from R&D, licensed externally, or even sold to reduce the company's cash pressure.
-
Chinese Pharma in "Innovation"
Time of Update: 2022-11-04
However, although China is currently the world's second largest pharmaceutical market, most Chinese pharmaceutical companies are still in the early stages of innovative drug development.
However, although China is currently the world's second largest pharmaceutical market, most Chinese pharmaceutical companies are still in the early stages of innovative drug development.
-
Niche tumors usher in new treatments, what other new drugs are worth looking forward to in the field of intrahepatic cholangiocarcinoma?
Time of Update: 2022-11-04
"Precision treatment of cholangiocarcinoma, preliminary clinical results of highly specific FGFR2 inhibitors are positive", WuXi AppTec, 2021 In September this year, Genoscience Pharma's new drug under development, GNS561, was granted orphan drug designation by the FDA for the treatment of intrahepatic cholangiocarcinoma.
-
After the new crown, the next arena for mRNA vaccines
Time of Update: 2022-11-01
Exclusive Original | Challenges and prospects of mRNA oncology vaccine development; Advances in Pharmacy In order to survive, the tumor staged "infernal affairs" in the battle with the immune system.
-
Neuropsychiatric field: Blue Ocean Circuit East Wind, Ten Thousand Kinds of Frost Heaven Race Free
Time of Update: 2022-11-01
Source: World Bank, Institute for Health Indicators and Evaluation, University of Washington, USA The field of neuropsychiatric diseases is full of unknown explorations and challenges, and the huge patient size and a large number of unmet clinical needs attract pharmaceutical companies to invest in new technologies and innovative drug research and development in this field.
-
Domestic innovative drugs are speeding up their overseas expansion! Another application for clinical trials of new drugs was accepted by the FDA
Time of Update: 2022-11-01
【Pharmaceutical Network Product Information】In recent years, with the improvement of the innovation and research and development capabilities of domestic pharmaceutical enterprises, domestic innovativ
-
First-line treatment of liver cancer, the FDA approved AstraZeneca's innovative immune combination therapy
Time of Update: 2022-11-01
A few days ago, the official website of the US FDA showed that the anti-CTLA-4 antibody Imjudo (tremelimumab) developed by AstraZeneca has been approved, in combination with the anti-PD-L1 antibody Imfinzi (durvalumab), to treat patients with unresectable hepatocellular carcinoma, providing liver cancer patients with a new immune combination therapy composed of dual immune checkpoint inhibitors.
-
China's ophthalmic drug competition pattern: Novartis leads, Bayer has the fastest growth rate, with an increase of 58.51%!
Time of Update: 2022-11-01
report 2021 Competitive Landscape of Ophthalmic Drugs in Retail Pharmacies Image source: Yaorong Cloud "White Paper on the Status and Future Development of China's Ophthalmic Industry" The market share of naphthalenevit eye drops has continued to lead in recent years.
-
Another multinational pharmaceutical company joins the spin-off tide!
Time of Update: 2022-11-01
For example, at the end of August, Novartis announced that it plans to divest 100% of its generic and biosimilar division Sandoz (Sandoz) into a newly listed independent operating company, which is expected to complete the spin-off process in the second half of 2023.
-
The 7th batch of drug collection, 14 provinces landing summary (collection)
Time of Update: 2022-11-01
At present, each province has successively issued notices on the implementation of the seventh batch of national procurement, which is summarized as follows: The Joint Procurement Office previously informed that the results of the seventh batch of national procurement will be implemented in November 2022, and the specific implementation date will be subject to the notice issued by various places.
-
FDA Success Stories, CDE Recommendations: How Does MIDD Accelerate New Drug R&D?
Time of Update: 2022-11-01
With the encouragement of innovative drug policies and the normalization of generic drug procurement, in less than 10 years, domestic traditional pharmaceutical companies have transformed and upgrade
-
Under the background of centralized procurement, the "patent cliff" of original drugs is accelerating
Time of Update: 2022-11-01
Figure 2: Proportion of sales of budesonide manufacturers over the years (%) PDB drug comprehensive database Correspondingly, the market shares of the selected enterprises Chia Tai Tianqing, Healthyuan, Changfeng Pharmaceutical and Pratt reached 18%, 8%, 6% and 11% respectively, accounting for a total of 43%, which has caught up with the original research, and it is expected that as the centralized procurement continues to be implemented, the market share of the selected enterprises will further increase.
-
Under the continued favorable policy, domestic Class 1 new drugs may begin to break out
Time of Update: 2022-11-01
【Pharmaceutical Network Policies and Regulations】Recently, the Administrative Committee of Foshan High-tech Zone issued the "Measures for Promoting the High-quality Development of Yundonghai Biomedica
-
Behind a four-year surge in market value of $200 billion, a pragmatic victory
Time of Update: 2022-11-01
The answer to the question needs to be found in Lilly's financial reports According to Eli Lilly's semi-annual report, the drugs that currently promote the company's performance growth are mainly dulaglutide, eqizumab, abeccilib, and empagliflozin baricitinib.
-
Sold for 570 million in half a year, where is the future of CAR-T in domestic competition
Time of Update: 2022-11-01
1. Extended reading: The second domestic BCMA-CAR-T declared for listing brief summary brief summary The research and development of CAR-T itself has the characteristics of high complexity, high cost and high risk, if there is no own differentiated advantage, coupled with high-priced drugs + difficult to market + fierce competition in target homogeneity, the commercialization of domestic CAR-T in the future has created a dead situation in the commercialization of domestic CAR-T in the future.
-
In 2022, the performance evaluation of public hospitals will be launched, and the centralized procurement of biosimilars needs to fully consider the characteristics of biological drugs, and especially expensive rare disease drugs cannot be included in medical insurance for the time being
Time of Update: 2022-11-01
Innovative equipment is directly hung on the net, or not included in the centralized procurement Recently, the Heilongjiang Provincial Public Resources Exchange Center issued the "Announcement on the Maintenance Information Results of Related Innovative and Clinically Urgently Needed Medical Consumables Hanging Network Enterprises".
